Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy

• Status: Completed
• Trial end date: 2004-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Intensive chemotherapy is often associated with low platelet counts often requiring platelet transfusions to maintain platelet counts. In previous clinical studies administration of rhTPO has been demonstrated to increase platelet counts.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: M.D. Anderson Cancer Center

Criteria

Inclusion Criteria:

• Confirmed new diagnosis of moderate or high-grade sarcoma (except leiomyosarcoma of gastrointestinal origin)

• Must have high risk disease by American Joint Committee on Cancer (AJCC) Staging System Stage IIC, III, or IV

• Must have recovered from surgery for a minimum of 2 weeks

• Must be scheduled for a minimum of 4 cycles of AI therapy

• Must be 13 years or older

• Must have ECOG performance status of 0, 1, or 2.

• Must have life expectancy of at least 12 weeks.

• Left ventricular ejection fraction must be more than 50%.

• Laboratory data within normal limits.

Exclusion Criteria:

• Prior front-line standard or experimental therapy for sarcoma

• History of bone marrow and or peripheral blood progenitor cell transplantation

• Prior pelvic radiation or radiation therapy to more than 25% of bone marrow reserves

• Prior treatment with megakaryocyte growth and differentiation factor

• Prior treatment with rhTPO

• History of platelet disorder

• History of myocardial infarction, stroke, pulmonary embolism, or deep vein thrombosis within the past 12 months

• Pregnant or lactating women

• Use of anticoagulants such as coumadin, heparin, etc.

• Known HIV or hepatitis